Lenalidomide and Vaccine Therapy in Treating Patients With Relapsed or Refractory Multiple Myeloma
Status:
Completed
Trial end date:
2010-09-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Biological therapies, such as lenalidomide, may stimulate the immune system in
different ways and stop cancer cells from growing. Vaccines may help the body build an
effective immune response to kill cancer cells. Giving lenalidomide together with vaccine
therapy may make a stronger immune response and kill more cancer cells.
PURPOSE: This phase II trial is studying how well giving lenalidomide together with vaccine
therapy works in treating patients with relapsed or refractory multiple myeloma.
Phase:
Phase 2
Details
Lead Sponsor:
Sidney Kimmel Comprehensive Cancer Center Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins